Lymphoma,%20T-Cell
Showing 26 - 50 of >10,000
NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)
Not yet recruiting
- NK/T Cell Lymphoma
- +2 more
-
Guangzhou, Guangdong, China
- +1 more
Jan 12, 2023
NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))
Not yet recruiting
- NK/T-cell Lymphoma
- Positron Emission Tomography/Magnetic Resonance (PET/MR)
-
Shanghai, Shanghai, ChinaRuijin Hospital
Dec 14, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell
Active, not recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +10 more
- Pembrolizumab
- Romidepsin
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)
Not yet recruiting
- Peripheral T Cell Lymphoma
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Jun 2, 2023
Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)
Not yet recruiting
- Peripheral T Cell Lymphoma
- Golidocitinib
- CHOP Regimen
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jul 18, 2023
Peripheral T Cell Lymphoma Trial in Duarte, Aurora, Philadelphia (Nivolumab and EPOCH)
Active, not recruiting
- Peripheral T Cell Lymphoma
- Nivolumab and EPOCH
-
Duarte, California
- +2 more
Jan 6, 2023
Cutaneous T Cell Lymphoma Trial in Chicago (APR-TD011 (RLF-TD011))
Not yet recruiting
- Cutaneous T Cell Lymphoma
- APR-TD011 (RLF-TD011)
-
Chicago, IllinoisDermatology CTU
Feb 6, 2023
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)
Not yet recruiting
- T-cell Lymphoma
- +10 more
-
Chicago, IllinoisRush University Medical Center
Oct 24, 2022
Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)
Not yet recruiting
- Relapsed or Refractory T-cell Lymphomas
-
Sendai-shi, Miyagi, JapanLocal Institution - 0001
Sep 12, 2023
Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)
Not yet recruiting
- Peripheral T Cell Lymphoma
- CAR-T Therapy
-
Hefei, Anhui, China
- +7 more
Jul 31, 2023
Minimal Residual Disease in Peripheral T-cell Lymphoma
Active, not recruiting
- Peripheral T Cell Lymphoma
- Tumor biopsy
- +2 more
-
Boston, Massachusetts
- +2 more
Dec 19, 2022
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,
Recruiting
- Cutaneous T-Cell Lymphoma
- +3 more
- Romidepsin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)
Not yet recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma
-
Kaohsiung, Taiwan
- +4 more
Apr 17, 2023
T Lymphoblastic Leukemia/Lymphoma Trial in Hangzhou (Chidamide)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
-
Hangzhou, Zhejiang, ChinaThe First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 7, 2023
Peripheral T Cell Lymphoma, Epigenetic Repression Trial in Tianjin (Chidamide, Azacitidine)
Recruiting
- Peripheral T Cell Lymphoma
- Epigenetic Repression
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jul 14, 2023
Cutaneous T Cell Lymphoma, Mycosis Fungoides Trial (Hypericin, Visible Light)
Not yet recruiting
- Cutaneous T Cell Lymphoma
- Mycosis Fungoides
- Hypericin
- Visible Light
- (no location specified)
May 23, 2023
T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)
Recruiting
- T Lymphoblastic Leukemia/Lymphoma
- CD7 CAR-T cells
-
Shenzhen, Guangdong, ChinaLi Yu
Nov 11, 2022
Skin Barrier and Microbiome of CTCL Patients
Not yet recruiting
- Lymphoma, T-Cell, Cutaneous
-
Leiden, NetherlandsCentre for Human Drug Research
Apr 21, 2023
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail
Recruiting
- T-cell Lymphoma
- +30 more
- Optional Blood Sample
- Optional Nail Sample
-
Duarte, California
- +25 more
Jul 28, 2023
Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)
Recruiting
- Peripheral T Cell Lymphoma
- Azacitidine Injection
- +6 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)
Not yet recruiting
- T-Cell Non-Hodgkin Lymphoma
- +14 more
- WU-CART-007
-
Saint Louis, MissouriWashington University School of Medicine
Jan 17, 2023
Peripheral T Cell Lymphoma (PTCL), Cell Therapy Trial in United States (MT-101, MT-101 + Conditioning (Lymphodepleting)
Recruiting
- Lymphoma, T-Cell, Peripheral
- +4 more
- MT-101
- MT-101 + Conditioning (Lymphodepleting) Chemotherapy
-
Duarte, California
- +8 more
Jan 27, 2023
Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma Trial in Boston (Microdevices, Standard of care therapy, Standard of care
Recruiting
- Cutaneous T Cell Lymphoma
- Peripheral T Cell Lymphoma
- Microdevices
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Jul 16, 2022
Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype Trial in Guangzhou (Chidamide combined with CHOP,
Recruiting
- Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
- Chidamide combined with CHOP
- Chidamide
-
Guangzhou, Guangdong, ChinaSun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Oct 7, 2022
Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
-
Tokyo, JapanTakeda Selected Site
Oct 11, 2022